BIOMARK’S LIQUID BIOPSY ASSAY LEVERING METABOLOMICS DEMONSTRATES STRONG PERFORMANCE FOR EARLY LUNG CANCER DETECTION
Vancouver, British Columbia – ( March 24th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection” has been published in the peer-reviewed journal Cancers, validating BioMark’s technology to detect early-stage (I/II) non-small cell lung cancer […]
BioMark Diagnostics Advanced Raman Spectrometer Could Potentially Serve as Complementary Detection Tool for COVID -19 / Coronavirus
Vancouver, British Columbia – (March 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, announced today following their annual technology meeting that their Advanced Raman Spectrometer might have potential to […]
BioMark’s Market Update Report
Vancouver, British Columbia – (February 4th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide a market update report with key activities undertaken by BioMark’s team during January 2020. “BioMark is not aware of any negative news that has impacted its share price recently. We continue to execute […]
BIOMARK’S SCIENTIFIC ADVISOR NAMED DEAN OF SCHULICH SCHOOL OF MEDICINE AND DENTISTRY
Vancouver, British Columbia – (January 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) and its team of scientific advisors would like to congratulate Dr. John Yoo for being named Dean of the Schulich School of Medicine & Dentistry on January 6th, 2020. Dr. Yoo has an international reputation as a pioneering […]
BIOMARK DIAGNOSTICS REVIEWS 2019 AND OUTLINES PLANS FOR 2020
Vancouver, British Columbia – (December 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to provide 2019 round up and our outlook for 2020. Below are key highlights. 2019 Round Up 2019 has been a transformative year for BioMark and we anticipate that 2020 would be another […]
BIOMARK CLOSES THE OVER-SUBSCRIBED PRIVATE PLACEMENT OFFERING
Vancouver, British Columbia – (December 16th, 2019) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of November 21st, 2019, it has closed the non-brokered private placement for gross proceeds of $669,347.00 wherein BioMark issued 2,231,157 units at a price […]
Canadian Trade Commissioner Service Features BioMark Diagnostics Next Generation Cancer Diagnostics
Vancouver, British Columbia – (December 11th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) with the help of the Canadian Trade Commissioner Service (TCS) is developing dynamic global connections and undertaking research collaborations in an effort to bring its “next-generation” cancer diagnostics technology to market. BioMark is excited and proud to […]
BIOMARK ANNOUNCES PRIVATE PLACEMENT
Vancouver, British Columbia – (November 21st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce a non-brokered Private Placement (the “Offering”). The Offering will be for up to 1,666,667 Units at a price of $0.30 to raise gross proceeds of up to $500,000. Each Unit is composed […]
BIOMARK Announces Private Placement
Press_Release_BIOMARK_ANNOUNCES_PRIVATE_PLACMENT_May_9th_2017 (PDF)
BioMark Signs Letter of Intent for Licensing Relationship for Clinical Validation and Development
Vancouver, British Columbia – (November 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has signed a Letter of Intent (LOI) with a Chinese company named GuangDong Longhu (Longhu) related to an anticipated licensing relationship. BioMark has been in discussions with Longhu and its management […]
